Talk:Cabergoline

From PsychonautWiki
Jump to navigation Jump to search
Songbird-egg.svg

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Summary sheet: Cabergoline
Cabergoline
Cabergoline.svg
Chemical Nomenclature
Common names Cabergoline, Dostinex
Systematic name (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.












DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions

Cabergoline is a chemical of the lysergamide and ergopeptine classes. It is a close derivative of LSD, more specifically, AL-LAD, but instead shares many effects with related, non-psychedelic medicinal compounds such as ergotamine, ergonovine or lisuride. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.

Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the dopamine D2 receptor as an agonist but has comparatively little effect on the serotonin 5-HT2A receptor where it acts as a partial agonist.

Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.[1][2]

See also

External links

References

  1. Krüger, T. H. C., Haake, P., Haverkamp, J., Krämer, M., Exton, M. S., Saller, B., Leygraf, N., Hartmann, U., Schedlowski, M. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". The Journal of Endocrinology. 179 (3): 357–365. doi:10.1677/joe.0.1790357. ISSN 0022-0795. 
  2. Hollander, A. B., Pastuszak, A. W., Hsieh, T.-C., Johnson, W. G., Scovell, J. M., Mai, C. K., Lipshultz, L. I. (March 2016). "Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis". Sexual Medicine. 4 (1): e28–33. doi:10.1016/j.esxm.2015.09.001. ISSN 2050-1161.